Californian medical company Second Sight has been granted conditional approval by the US Food and Drug Administration to a small clinical trial of its new device , the Orion , which could restore some vision to patients with retinitis A . The Orion takes much of its technology from Second Sight 's previous device , the Argus II , but also includes devices implanted directly into the brain to bypass the brain and the optic nerve . Delivering electrical pulses here should tell the brain to perceive patterns of light. The company said people who are blind due to other illnesses could " hypothetically " use the Orion .
Californian medical company Second Sight has been granted conditional approval by the US Food and Drug Administration to a small clinical trial of its new device , the Orion , which could restore some vision to patients with retinitis A . The Orion takes much of its technology from Second Sight 's previous device , the Argus II , but also includes devices implanted directly into the brain to bypass the brain and the optic nerve . The company said people who are blind due to other illnesses could " hypothetically " use the Orion .